We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+17.87%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$39.3M
Cap. Flow
+$15.2M
Cap. Flow %
5.83%
Top 10 Hldgs %
55.54%
Holding
65
New
16
Increased
14
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$6.2M
2
AKAO
Achaogen Inc
AKAO
+$5.75M
3
BMY icon
Bristol-Myers Squibb
BMY
+$5.38M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.36M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.71M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$11.6M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$8.18M
3
AERI
Aerie Pharmaceuticals
AERI
+$5.49M
4
GILD icon
Gilead Sciences
GILD
+$5.2M
5
SHPG
Shire pic
SHPG
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
51
MacroGenics
MGNX
$260M
$1M 0.38%
54,000
– –
FOMX
52
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$979K 0.37%
197,838
– –
LGND icon
53
Ligand Pharmaceuticals
LGND
$5.67B
$952K 0.36%
14,427
-33,663
-70% -$2.21M
RDUS
54
DELISTED
Radius Health, Inc.
RDUS
$765K 0.29%
19,799
– –
PCRX icon
55
Pacira BioSciences
PCRX
$1.03B
$729K 0.28%
+16,000
New +$692K
ARRY
56
DELISTED
Array Biopharma Inc
ARRY
$693K 0.27%
77,500
+12,500
+19% +$133K
AERI
57
DELISTED
Aerie Pharmaceuticals
AERI
$680K 0.26%
15,000
-123,000
-89% -$5.49M
ALDR
58
DELISTED
Alder Biopharmaceuticals
ALDR
$498K 0.19%
24,000
-56,000
-70% -$1.24M
XNCR icon
59
Xencor
XNCR
$2.15B
$430K 0.16%
18,000
-30,000
-63% -$723K
ADAP
60
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-96,419
Closed -$387K
FOLD
61
DELISTED
Amicus Therapeutics
FOLD
– –
-55,000
Closed -$273K
SRPT icon
62
Sarepta Therapeutics
SRPT
$2.28B
– –
-21,000
Closed -$576K
ACOR
63
DELISTED
Acorda Therapeutics
ACOR
– –
-183
Closed -$414K
ARIA
64
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-657,912
Closed -$8.18M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2017 Portfolio in Review

As of Q1 2017, International Biotechnology Trust held 65 positions worth $261M, up 18% from $222M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

International Biotechnology Trust deployed $15.2M of net new capital in Q1 2017, opening 16 new positions and adding to 14 existing holdings. Its largest new stake was Achaogen Inc: 280,038 shares worth $7.07M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was TESARO, Inc., an estimated $11.6M trimmed.

  • International Biotechnology Trust's largest Q1 2017 buy was Achaogen Inc: 280,038 shares worth $7.07M.
  • International Biotechnology Trust added most to Incyte in Q1 2017, an estimated $6.2M increase.
  • International Biotechnology Trust's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $11.6M.
  • International Biotechnology Trust fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $8.18M.
  • International Biotechnology Trust's ten largest holdings make up 56% of its $261M portfolio in Q1 2017.
  • International Biotechnology Trust opened 16 new positions and closed 5 in Q1 2017.
  • International Biotechnology Trust's portfolio value rose 18% quarter-over-quarter to $261M.

Based on International Biotechnology Trust's 13F filing for Q1 2017, filed 2 Mar 2018.